Key facts
- It has raised $5.1M; the latest was Later Stage VC ($5.1M) in Nov 2025.
- Notable investors include European Innovation Council, GO Capital, Critical Path Ventures, Imperial College London, La Synapse.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Alkion BioInnovations
- ·The full record, as it builds
Funding rounds
No funding rounds for Alkion BioInnovations are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alkion BioInnovations
Producer of natural plant active ingredients designed for pharmaceutical applications using proprietary patented semi-industrial technologies. The company's technology utilizes plant science to develop new pharmaceutical and agri-food products, focusing on natural ingredients and extraction processes to create effective products, enabling industries to deliver services to the pharmaceutical and agri-food markets that are both environmentally friendly and beneficial to consumers.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2011
- Employees
- 14
- Website
- alkinnov.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Alkion BioInnovations doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alkion BioInnovations shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alkion BioInnovations in its N-PORT filings yet. We sweep new filings monthly.